Targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
15
NCT05533242
Radioimmunotherapy with Lu-177 Labeled 6A10 Fab-fragments in Patients with Glioblastoma After Standard Treatment
Phase: Phase 1
Role: Collaborator
Start: Jan 22, 2024
Completion: Apr 30, 2026
Loading map...